Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2)

13 août 2026 mis à jour par: Min Chul Kim, Chonnam National University Hospital

OPtimal TIming of Staged Complete RevascularizatiON in ST-Segment Elevation Myocardial Infarction With Multivessel Disease: The OPTION-STEMI2 Trial

This prospective, multicenter, open-label, superiority trial will enroll patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease. Following successful percutaneous coronary intervention (PCI) of the infarct-related artery (IRA), patients who meet the eligibility criteria will be randomized in a 1:1 ratio to either in-hospital staged complete revascularization with PCI of non-IRA lesions performed on a separate day during hospitalization, at least 48 hours after PCI of the IRA, or out-of-hospital staged complete revascularization with PCI of non-IRA lesions performed after discharge between 15 and 45 days of randomization. In both groups, non-IRA lesions with 50-69% stenosis will be evaluated using FFR.

Aperçu de l'étude

Description détaillée

  • Study Objectives: To determine the optimal timing of staged complete revascularization guided by fractional flow reserve (FFR) (in-hospital staged complete revascularization vs. out-of-hospital staged complete revascularization) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
  • Study Background: Approximately half of patients with STEMI have multivessel coronary artery disease, which is associated with worse clinical outcomes than single vessel disease. Complete revascularization has become the standard interventional strategy for the management of these patients. Regarding the timing of complete revascularization, two recent randomized clinical trials demonstrated that immediate complete revascularization was non-inferior to staged complete revascularization in patients with STEMI. In this context, the 2023 European guidelines give a class IA recommendation for complete revascularization, either during the index procedure or within 45 days. The 2025 American guidelines recommend immediate complete revascularization with a class IIb recommendation for hemodynamically stable patients with STEMI and low-complex anatomy. However, in these trials, planned staged revascularization in the staged group was performed after hospital discharge rather than during the index admission. In those previous trials, the timing of staged revascularization was median 15 days (IQR 4-28) in the BIOVASC trial and median 37 days (IQR 30-43) in the MULTISTARS AMI trial, and most clinical events in the staged group (mainly due to unplanned revascularization and myocardial infarction) had occurred during the early phase after the index procedure with the possibility of progression of a non-infarct related artery (non-IRA) lesion before the staged procedure. Greater inflammatory status during the acute phase of myocardial infarction might be associated with these findings. The OPTION-STEMI trial, which compared immediate and staged complete revascularization during index hospitalization, failed to demonstrate non-inferiority for the primary endpoint at 1 year (13% in the immediate complete revascularization group and 11% in the staged complete revascularization group; hazard ratio 1.24; 95% confidence interval 0.86-1.79; P for non-inferiority = 0.024). Therefore, it remains unclear whether the treatment effect differs between in-hospital and out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. The investigators designed a prospective, open-label, multicenter, superiority trial to evaluate the efficacy and safety of in-hospital staged complete revascularization compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease. Non-IRA lesions with 50-69% stenosis will be assessed using FFR, whereas those with ≥ 70% stenosis will undergo revascularization without FFR assessment. The investigators hypothesize that in-hospital staged complete revascularization may mitigate the risk of early progression of non-IRA lesions, compared with out-of-hospital staged complete revascularization, without increasing the procedural risk associated with immediate complete revascularization.
  • Study Hypothesis: In-hospital staged complete revascularization would reduce the risk of the primary composite endpoint (a composite of all-cause death, non-fatal myocardial infarction, or all unplanned revascularization) at 12 months compared with out-of-hospital staged complete revascularization in patients with STEMI and multivessel disease.

Type d'étude

Interventionnel

Inscription (Estimé)

1252

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Min Chul Kim, MD, PhD
  • Numéro de téléphone: 82-10-4606-2643
  • E-mail: kmc3242@hanmail.net

Lieux d'étude

      • Bucheon-si, Corée du Sud
        • Bucheon Sejong Hospital
      • Changwon, Corée du Sud
        • Gyeongsang National University Changwon Hospital
      • Changwon, Corée du Sud
        • Samsung Changwon Medical Center
      • Cheonan, Corée du Sud
        • Soon Chun Hyang University Hospital Cheonan
      • Cheongju-si, Corée du Sud
        • Chungbuk National University Hospital
      • Chuncheon, Corée du Sud
        • Kangwon National University Hospital
      • Daegu, Corée du Sud
        • Keimyung University Dongsan Hospital
      • Daegu, Corée du Sud
        • Kyungpook National University Hospital
      • Daegu, Corée du Sud
        • Daegu Catholic University Medical Center
      • Daegu, Corée du Sud
        • Yeongnam University Medical Center
      • Daejeon, Corée du Sud
        • Chungnam National University Hospital
      • Gwangju, Corée du Sud
        • Chonnam National University Hospital
      • Gwangju, Corée du Sud
        • Chosun University Hospital
      • Gwangju, Corée du Sud
        • Gwangju Veterans Hospital
      • Gwangju, Corée du Sud
        • Kwangju Christian Hospital
      • Gwangmyeong, Corée du Sud
        • Chung-Ang University Gwangmyeong Hospital
      • Jeju City, Corée du Sud
        • Jeju National University Hospital
      • Jeonju, Corée du Sud
        • Jeonbuk National University Hospital
      • Jeonju, Corée du Sud
        • Presbyterian Medical Center
      • Jinju, Corée du Sud
        • Gyeongsang National University Hospital
      • Pusan, Corée du Sud
        • Pusan National University Hospital
      • Pusan, Corée du Sud
        • Inje University Haeundae Paik Hospital
      • Pusan, Corée du Sud
        • Inje University Busan Paik Hospital
      • Pusan, Corée du Sud
        • Kosin University Gospel Hospital
      • Seoul, Corée du Sud
        • Korea University Anam Hospital
      • Seoul, Corée du Sud
        • Koera University Guro Hospital
      • Seoul, Corée du Sud
        • Yonsei University Health System, Gangnam Severance Hospital
      • Suncheon, Corée du Sud
        • St. Carollo General Hospital
      • Suwon, Corée du Sud
        • Ajou University Hospital
      • Yangsan, Corée du Sud
        • Pusan National University Yangsan Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  • Age ≥19 years
  • ST-segment elevation myocardial infarction (STEMI): ST-segment elevation ≥ 0.1 mV in at least two contiguous leads, or New-onset left bundle branch block (LBBB)
  • Primary PCI within 12 h after symptom development
  • At least 1 non-infarct related artery (non-IRA) with diameter ≥ 2.5 mm and 50% stenosis by visual estimation

Exclusion Criteria:

  • Cardiogenic shock at initial presentation or after infarct-related artery (IRA) treatment
  • Thrombolysis in myocardial infarction flow at non-IRA ≤ 2
  • Severe procedural complications during primary percutaneous coronary intervention that, in the judgement of the operator, preclude study enrollment
  • Non-IRA lesion unsuitable for percutaneous coronary intervention (PCI) treatment that, in the judgement of the operator, preclude study enrollment
  • Chronic total occlusion in a non-IRA
  • History of anaphylaxis to contrast agent
  • Pregnancy and lactation
  • Life expectancy < 1 year
  • Severe valvular heart disease
  • History of coronary artery bypass grafting (CABG) or planned CABG
  • Fibrinolysis therapy prior to admission
  • Severe asthma

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Out-of-hospital staged complete revascularization
In the out-of-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
PCI of non-IRA lesions will be performed after discharge and between 15 and 45 days of randomization. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
Expérimental: In-hospital staged complete revascularization
In the in-hospital staged complete revascularization group, PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.
PCI of non-IRA lesions will be performed on a separate day during the index hospitalization, at least 48 hours after PCI of the IRA. Non-IRA lesion which have equal or more than 70% diameter stenosis by visual estimation will be revascularized without FFR evaluation. Non-IRA lesion with diameter stenosis 50-69% by visual estimation will be evaluated using FFR device. In case of FFR value more than 0.8, non-IRA lesion will be deferred without PCI. If FFR value was equal or less than 0.8, non-IRA lesion will be revascularized.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Délai: At 12 months after randomization
At 12 months after randomization

Mesures de résultats secondaires

Mesure des résultats
Délai
Composite of all-cause death, nonfatal myocardial infarction, or all unplanned revascularization
Délai: At 1, 6, 24, 36, 48, and 60 months after randomization
At 1, 6, 24, 36, 48, and 60 months after randomization
All-cause death
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal myocardial infarction
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
All unplanned revascularization
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Cardiac death
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-cardiac death
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal spontaneous myocardial infarction
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Nonfatal procedure-related myocardial infarction
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-lesion revascularization
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Target-vessel revascularization
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Non-target vessel revascularization
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for unstable angina
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Hospitalization for heart failure
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stent thrombosis
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Stroke
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Major bleeding
Délai: At 1, 6, 12, 24, 36, 48, and 60 months after randomization
At 1, 6, 12, 24, 36, 48, and 60 months after randomization
Contrast-induced nephropathy
Délai: At hospital discharge (up to 30 days)
At hospital discharge (up to 30 days)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Youngkeun Ahn, MD, PhD, Chonnam National University Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 septembre 2026

Achèvement primaire (Estimé)

31 juillet 2031

Achèvement de l'étude (Estimé)

31 juillet 2035

Dates d'inscription aux études

Première soumission

26 juillet 2026

Première soumission répondant aux critères de contrôle qualité

30 juillet 2026

Première publication (Réel)

3 août 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

17 août 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner